5-aminofluorescein profile

5-Aminofluorescein is a fluorescent dye that has been widely used in biological research. It is synthesized through a series of reactions starting with the condensation of resorcinol with phthalic anhydride to form fluorescein, followed by nitration and reduction to yield the desired 5-aminofluorescein. The compound exhibits strong fluorescence in the green region of the visible spectrum, making it ideal for applications such as cell imaging, protein labeling, and DNA detection. Its ability to interact with specific biological targets allows for the visualization of cellular processes and the study of molecular interactions. 5-Aminofluorescein is also known for its photostability and high quantum yield, contributing to its popularity in fluorescence microscopy. The compound has found applications in various fields, including bioimaging, drug delivery, and biosensing.'

5-aminofluorescein: used to determine progesterone in human serum or plasma [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

5-aminofluorescein : A primary amino compound that is fluorescein carrying an amino substituent at C-5. Building block/intermediate for the synthesis of the fluorescent dye flourescein; also used to produce N-(fluorescein-5-yl)maleamic acid. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	76845
CHEBI ID	91078
SCHEMBL ID	220211
MeSH ID	M0097395

Synonym
1-aminofluorescein
einecs 222-043-6
spiro(isobenzofuran-1(3h),9'-(9h)xanthen)-3-one, 5-amino-3',6'-dihydroxy-
fluoresceinamine isomer i
spiro[isobenzofuran-1(3h),9'-[9h]xanthen]-3-one, 5-amino-3',6'-dihydroxy-
4-aminofluorescein
3326-34-9
fluorescein, 5-amino-
fluoresceinamine-i
6-amino-3',6'-dihydroxy-spiro[isobenzofuran-3,9'-xanthene]-1-one
5-aminofluorescein
fluorescein amine isomer 1
fluoresceinamine, isomer i
F-2945
5-amino-3',6'-dihydroxyspiro[isobenzofuran-1(3h),9'-(9h)xanthen]-3-one
A0306
gzajoegtzdusks-uhfffaoysa-
inchi=1/c20h13no5/c21-10-1-4-14-13(7-10)19(24)26-20(14)15-5-2-11(22)8-17(15)25-18-9-12(23)3-6-16(18)20/h1-9,22-23h,21h2
fluoresceinamine
6-amino-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one
FT-0626461
FT-0626459
FT-0626462
AKOS015903353
SCHEMBL220211
CS-3856
fluorescein-5-amine
CHEBI:91078
5-amino-3',6'-dihydroxy-3h-spiro[2-benzofuran-1,9'-xanthen]-3-one
5-amino-fluorescein
n-(fluorescein-5-yl)amine
DTXSID0062979
fluoresceinamine isomer 1
J-100014
5-amino-3',6'-dihydroxy-3h-spiro[2-benzofuran-1,9'-xanthene]-3-one
J-650336
HY-D0022
mfcd00005052
fluorescein amine isomer i
mfcd00133331
GS-3082
EX-A1779
5-amino-3',6'-dihydroxy-3h-spiro[isobenzofuran-1,9'-xanthen]-3-one ,
BCP20888
5-afm
Q27163049
SY029055
AM10011
5-aminofluorescein (isomer i)
5-af
H10388
A875348
EN300-7400097
fluoresceinamine, isomer 1
PD063767
F04-0033
YY8M286SWU
5-amino-3',6'-dihydroxyspiro[isobenzofuran-1(3h),9'-[9h]xanthen]-3-one

Excerpt	Reference	Relevance
"85 mL/h), and a long elimination half-life (mean T(1/2;β) = 307 hours)."	( Pharmacokinetics of 5-aminofluorescein-albumin, a novel fluorescence marker of brain tumors during surgery. Ding, R; Fardanesh, M; Frei, E; Haefeli, WE; Kremer, P; Schrenk, HH, 2011)	0.69

Excerpt	Reference	Relevance
" First of all, we verified that P80 promoted the bioavailability of MEHP-AF in the long-term and low-dose exposure of MEHP-AF with P80 as a result of increasing the intestinal absorption of MEHP-AF."	( Food emulsifier polysorbate 80 promotes the intestinal absorption of mono-2-ethylhexyl phthalate by disturbing intestinal barrier. Feng, QP; Hu, MY; Li, WJ; Wu, X; Xiang, SY; Yu, SQ; Yuan, YZ; Zhu, YT, 2021)	0.62

Class	Description
primary amino compound	A compound formally derived from ammonia by replacing one hydrogen atom by an organyl group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	6 (20.00)	18.7374
1990's	3 (10.00)	18.2507
2000's	5 (16.67)	29.6817
2010's	12 (40.00)	24.3611
2020's	4 (13.33)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (3.33%)	5.53%
Reviews	0 (0.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	29 (96.67%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
chlorine chloride : A halide anion formed when chlorine picks up an electron to form an an anion.	2.07	1	0	halide anion; monoatomic chlorine	cofactor; Escherichia coli metabolite; human metabolite
bisbenzimidazole Bisbenzimidazole: A benzimidazole antifilarial agent; it is fluorescent when it binds to certain nucleotides in DNA, thus providing a tool for the study of DNA replication; it also interferes with mitosis.	1.97	1	0	bibenzimidazole; N-methylpiperazine	anthelminthic drug; fluorochrome
erythrosine Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.	6.15	30	1
tyrosine Tyrosine: A non-essential amino acid. In animals it is synthesized from PHENYLALANINE. It is also the precursor of EPINEPHRINE; THYROID HORMONES; and melanin.. tyrosine : An alpha-amino acid that is phenylalanine bearing a hydroxy substituent at position 4 on the phenyl ring.	2.17	1	0	amino acid zwitterion; erythrose 4-phosphate/phosphoenolpyruvate family amino acid; L-alpha-amino acid; proteinogenic amino acid; tyrosine	EC 1.3.1.43 (arogenate dehydrogenase) inhibitor; fundamental metabolite; micronutrient; nutraceutical
cysteamine Cysteamine: A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.. cysteamine : An amine that consists of an ethane skeleton substituted with a thiol group at C-1 and an amino group at C-2.	2.1	1	0	amine; thiol	geroprotector; human metabolite; mouse metabolite; radiation protective agent
maleic anhydride Maleic Anhydrides: Used in copolymerization reactions, in the Diels-Alder(diene)synthesis, in the preparation of resins, pharmaceuticals and agricultural chemicals. It is a powerful irritant and causes burns.. maleic anhydride : A cyclic dicarboxylic anhydride that is the cyclic anhydride of maleic acid.	2.49	2	0	cyclic dicarboxylic anhydride; furans	allergen
diethylhexyl phthalate Diethylhexyl Phthalate: An ester of phthalic acid. It appears as a light-colored, odorless liquid and is used as a plasticizer for many resins and elastomers.. bis(2-ethylhexyl) phthalate : A phthalate ester that is the bis(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid.	2.76	2	0	diester; phthalate ester	androstane receptor agonist; apoptosis inhibitor; plasticiser
thiazoles [no description available]	1.97	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
isovalerylaldehyde isovalerylaldehyde: structure in Merck Index, 9th ed, #5093. 3-methylbutanal : A methylbutanal that is butanal substituted by a methyl group at position 3. It occurs as a volatile constituent in olives.	2.06	1	0	methylbutanal	flavouring agent; plant metabolite; Saccharomyces cerevisiae metabolite; volatile oil component
sodium hydroxide Sodium Hydroxide: A highly caustic substance that is used to neutralize acids and make sodium salts. (From Merck Index, 11th ed)	2	1	0	alkali metal hydroxide
6-methoxyquinoline 6-methoxyquinoline: RN given refers to parent cpd. 6-methoxyquinoline : An aromatic ether that is quinoline substituted at position 6 by a methoxy group.	2.07	1	0	aromatic ether; quinolines
fluorescein Fluorescein: A phthalic indicator dye that appears yellow-green in normal tear film and bright green in a more alkaline medium such as the aqueous humor.. fluorescein (lactone form) : A xanthene dye that is highly fluorescent, detectable even when present in minute quantities. Used forensically to detect traces of blood, in analytical chemistry as an indicator in silver nitrate titrations and in microscopy.	2.05	1	0	2-benzofurans; gamma-lactone; organic heteropentacyclic compound; oxaspiro compound; polyphenol; xanthene dye	fluorescent dye; radioopaque medium
fluorescein-5-isothiocyanate Fluorescein-5-isothiocyanate: Fluorescent probe capable of being conjugated to tissue and proteins. It is used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.. fluorescein 5-isothiocyanate : The 5-isomer of fluorescein isothiocyanate. Acts as a fluorescent probe capable of being conjugated to tissue and proteins; used as a label in fluorescent antibody staining procedures as well as protein- and amino acid-binding techniques.	2.4	2	0	fluorescein isothiocyanate
mono-(2-ethylhexyl)phthalate mono-(2-ethylhexyl)phthalate: RN given refers to parent cpd. mono(2-ethylhexyl) phthalate : The mono(2-ethylhexyl) ester of benzene-1,2-dicarboxylic acid.	2.76	2	0	phthalic acid monoester
peroxynitrous acid Peroxynitrous Acid: A potent oxidant synthesized by the cell during its normal metabolism. Peroxynitrite is formed from the reaction of two free radicals, NITRIC OXIDE and the superoxide anion (SUPEROXIDES).	2.07	1	0	nitrogen oxoacid
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	2.11	1	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
maleic acid maleic acid: RN given refers to parent cpd(Z)-isomer which is maleic acid; all RR's given refer to (Z)-isomer; (E)-isomer is fumaric acid. maleic acid : A butenedioic acid in which the double bond has cis- (Z)-configuration.	2.06	1	0	butenedioic acid	algal metabolite; mouse metabolite; plant metabolite
cyanoginosin lr cyanoginosin LR: cyclic heptapeptide from cyanobacterium Microcystis aeruginosa. microcystin-LR : A microcystin consisting of D-alanyl, L-leucyl, (3S)-3-methyl-D-beta-aspartyl,L-arginyl, 2S,3S,4E,6E,8S,9S)-3-amino-4,5,6,7-tetradehydro-9-methoxy-2,6,8-trimethyl-10-phenyldecanoyl, D-gamma-glutamyl, and 2,3-didehydro-N-methylalanyl residues joined into a 25-membered macrocycle. Produced by the cyanobacterium Microcystis aeruginosa, it is the most studied of the microcystins.	2.41	1	0	microcystin	bacterial metabolite; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; environmental contaminant; xenobiotic
maleamic acid maleamic acid: structure. maleamic acid : A dicarboxylic acid monoamide of maleamic acid.	2.1	1	0	alpha,beta-unsaturated monocarboxylic acid; dicarboxylic acid monoamide	bacterial xenobiotic metabolite; Escherichia coli metabolite
carbocyanines Carbocyanines: Compounds that contain three methine groups. They are frequently used as cationic dyes used for differential staining of biological materials.	2.31	1	0	cyanine dye; organic iodide salt	fluorochrome
10-hydroxystearic acid 10-hydroxystearic acid: structure given in first source; see also record for 10(9)-hydroxystearic acid. 10-hydroxyoctadecanoic acid : A hydroxy fatty acid that is octadecanoic acid carrying a hydroxy group at position 10.	2.02	1	0	hydroxy fatty acid; long-chain fatty acid	bacterial xenobiotic metabolite
10(9)-hydroxystearic acid 10(9)-hydroxystearic acid: structure; RN given refers to parent cpd; see also records for 9-hydroxystearic acid & 10-hydroxystearic acid. 9-hydroxyoctadecanoic acid : A hydroxyoctadecanoic acid that is octadecanoic acid (stearic acid) which has been substituted by a hydroxy group at position 9.	2.02	1	0	hydroxyoctadecanoic acid
chitosan [no description available]	2.31	1	0
trypan blue Trypan Blue: A diazo-naphthalene sulfonate that is widely used as a stain.. trypan blue : An organosulfonate salt that is the tetrasodium salt of 3,3'-[(3,3'-dimethylbiphenyl-4,4'-diyl)didiazene-2,1-diyl]bis(5-amino-4-hydroxynaphthalene-2,7-disulfonic acid).	1.99	1	0

Condition	Relationship Strength	Studies	Trials
Colorectal Cancer [description not available]	2.41	1	0
Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.	2.41	1	0
Bone Diseases Diseases of BONES.	2.1	1	0
Breast Cancer [description not available]	2.11	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	2.11	1	0
Benign Neoplasms, Brain [description not available]	3.85	2	1
Astrocytoma, Grade IV [description not available]	2.05	1	0
Glial Cell Tumors [description not available]	2.05	1	0
Arachnoidal Cerebellar Sarcoma, Circumscribed [description not available]	2.05	1	0
Anaplastic Oligodendroglioma [description not available]	2.05	1	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	3.85	2	1
Glioblastoma A malignant form of astrocytoma histologically characterized by pleomorphism of cells, nuclear atypia, microhemorrhage, and necrosis. They may arise in any region of the central nervous system, with a predilection for the cerebral hemispheres, basal ganglia, and commissural pathways. Clinical presentation most frequently occurs in the fifth or sixth decade of life with focal neurologic signs or seizures.	2.05	1	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.05	1	0
Medulloblastoma A malignant neoplasm that may be classified either as a glioma or as a primitive neuroectodermal tumor of childhood (see NEUROECTODERMAL TUMOR, PRIMITIVE). The tumor occurs most frequently in the first decade of life with the most typical location being the cerebellar vermis. Histologic features include a high degree of cellularity, frequent mitotic figures, and a tendency for the cells to organize into sheets or form rosettes. Medulloblastoma have a high propensity to spread throughout the craniospinal intradural axis. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2060-1)	2.05	1	0
Oligodendroglioma A relatively slow-growing glioma that is derived from oligodendrocytes and tends to occur in the cerebral hemispheres, thalamus, or lateral ventricle. They may present at any age, but are most frequent in the third to fifth decades, with an earlier incidence peak in the first decade. Histologically, these tumors are encapsulated, relatively avascular, and tend to form cysts and microcalcifications. Neoplastic cells tend to have small round nuclei surrounded by unstained nuclei. The tumors may vary from well-differentiated to highly anaplastic forms. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, p2052; Adams et al., Principles of Neurology, 6th ed, p655)	2.05	1	0
Heart Disease, Ischemic [description not available]	2.07	1	0
Myocardial Ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).	2.07	1	0
Electrolytes Substances that dissociate into two or more ions, to some extent, in water. Solutions of electrolytes thus conduct an electric current and can be decomposed by it (ELECTROLYSIS). (Grant & Hackh's Chemical Dictionary, 5th ed)	2	1	0

5-aminofluorescein

Description

Cross-References

Synonyms (58)

Research Excerpts

Pharmacokinetics

Bioavailability

Drug Classes (1)

Research

Studies (30)

Market Indicators

Research Demand Index: 26.06

Study Types